Physician profile
Robert Thomas Jackson
NPI 1992806723
$3,784.12
in general payments reported to CMS, 2019-2025
34 companies · $24.74 in 2025
The $24.74 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,547 · 2022: $1,461 · 2023: $752 · 2025: $24.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $688.60 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $487.75 | 2021-2023 | Jardiance |
| Amarin Pharma, INC. | $284.33 | 2021-2023 | |
| Novo Nordisk INC | $280.91 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $203.51 | 2021-2023 | Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $179.83 | 2021-2023 | Mounjaro |
| Currax Pharmaceuticals LLC | $129.41 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $108.80 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $107.22 | 2021-2023 | Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $97.46 | 2021-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $95.17 | 2021-2022 | |
| Amgen INC. | $91.47 | 2021-2022 | |
| Althera Pharmaceuticals LLC | $84.10 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $83.08 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $76.36 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $75.99 | 2022-2023 | Rexulti |
| Pfizer INC. | $75.20 | 2022-2023 | |
| Abbott Laboratories | $69.99 | 2022-2025 | Gallant |
| Genentech USA, INC. | $63.48 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $62.53 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $62.28 | 2022 | |
| Almatica Pharma LLC | $41.86 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $41.33 | 2021-2022 | |
| Adlon Therapeutics L.P. | $40.46 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $39.26 | 2021-2022 | |
| Ibsa Pharma INC. | $38.58 | 2022 | |
| Xeris Pharmaceuticals, INC. | $37.86 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.80 | 2022-2023 | Cycloset |
| Bausch Health US, LLC | $31.75 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.87 | 2021 | |
| Acerus Pharmaceuticals Corporation | $15.22 | 2021 | |
| Dexcom, INC. | $14.25 | 2022 | |
| Astellas Pharma US INC | $14.00 | 2021 | |
| Si-Bone, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.